Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 5:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary Vascular Disorder Clear all
Terminated Phase 2 Interventional Results available

The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting

NCT00467896
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Iloprost PD-6, Iloprost PD-15
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 85 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
12
States / cities
Phoenix, Arizona • La Jolla, California • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Jun 25, 2026, 5:02 PM EDT
Completed Phase 1 Interventional

Mycophenolate Mofetil to Treat Wegener's Granulomatosis and Related Vascular Inflammatory Conditions

NCT00001764
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 25, 2026, 5:02 PM EDT
Completed Phase 3 Interventional Results available

A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT01178073
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
ambrisentan, tadalafil
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
61
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Jun 25, 2026, 5:02 PM EDT
Completed Phase 1 Interventional

Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension

NCT00023296
View directory record Official record
Conditions
Sickle Cell Anemia, Pulmonary Hypertension
Interventions
Nitric Oxide, INO Pulse - NO Delivery System
Drug · Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jun 25, 2026, 5:02 PM EDT
Completed Phase 3 Interventional Results available

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)

NCT04576988
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sotatercept, Placebo, Background PAH Therapy
Biological · Drug
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jun 25, 2026, 5:02 PM EDT
Completed Phase 1 Interventional Results available

Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)

NCT04370873
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Frespaciguat, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
40 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Lexington, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Jun 25, 2026, 5:02 PM EDT
Withdrawn No phase listed Observational

Single Center Post-Market Study of Thrombolytic Therapy Using the Versus™ Catheter

NCT06975969
View directory record Official record
Conditions
Blood Clots, Vascular Disease, Embolism Thrombosis, Cardiovascular Diseases, Lung Diseases
Interventions
Versus™ Endovascular Pulmonary Artery Drug Delivery Catheter
Device
Lead sponsor
Liquet Medical Inc.
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jun 25, 2026, 5:02 PM EDT
Completed Not applicable Interventional

Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients

NCT04604158
View directory record Official record
Conditions
Cancer, Cancer Metastatic, Neoplasms, Breast Cancer, Lung Cancer, Glioblastoma, Prostate Cancer, Gynecologic Cancer, Colorectal Cancer, Sarcoma, Kidney Cancer, Bladder Cancer, Lymphoma, Leukemia, Head and Neck Cancer, Pancreas Cancer, Multiple Myeloma, Anxiety, Social Isolation, Stress, Loneliness, Melanoma, Uterine Cancer
Interventions
Elly Mobile Phone Application
Behavioral
Lead sponsor
Gillian Gresham
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Jun 25, 2026, 5:02 PM EDT
Completed Not applicable Interventional

A Prospective Study to Determine the Effectiveness of Reaming in Reducing Fat Emboli to the Lungs

NCT00327158
View directory record Official record
Conditions
Diaphyseal Femur Fracture
Interventions
Transesophageal transducer, echocardiography
Procedure
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 27, 2010 · Synced Jun 25, 2026, 5:02 PM EDT
Completed Phase 1 Interventional

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

NCT00036790
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
doxorubicin hydrochloride, motexafin gadolinium
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jun 25, 2026, 5:02 PM EDT
Completed Not applicable Interventional

Telestroke at Comprehensive Stroke Center During the COVID-19 Pandemic

NCT04761874
View directory record Official record
Conditions
Stroke, Acute
Interventions
Telestroke
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Edina, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Jun 25, 2026, 5:02 PM EDT
Not listed No phase listed Observational

Outcomes Data of Adipose Stem Cells to Treat Chronic Obstructive Pulmonary Disease

NCT02348060
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
StemGenex
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Jun 25, 2026, 5:02 PM EDT
Recruiting Phase 3 Interventional

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

NCT07213778
View directory record Official record
Conditions
Symptomatic Venous Thromboembolism (VTE)
Interventions
REGN7508, Acetylsalicylic Acid (ASA), Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
23
States / cities
Rancho Mirage, California • Lone Tree, Colorado • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jun 25, 2026, 5:02 PM EDT
Completed Not applicable Interventional Results available

The SENTRY Clinical Study

NCT01975090
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis
Interventions
SENTRY IVC Filter
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
20
States / cities
Birmingham, Alabama • Palo Alto, California • Colorado Springs, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Jun 25, 2026, 5:02 PM EDT
Terminated Phase 4 Interventional Results available

Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism

NCT04558125
View directory record Official record
Conditions
Pulmonary Embolism, COVID
Interventions
TNKase, Placebo, Enoxaparin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Jun 25, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer

NCT00320255
View directory record Official record
Conditions
Thrombosis, Cancer, Pulmonary Embolism
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 90 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Jun 25, 2026, 5:02 PM EDT
Completed Phase 1 Interventional

Diagnostic Effectiveness of Virtual Bronchoscopy

NCT00001515
View directory record Official record
Conditions
Bronchogenic Carcinoma, Chronic Granulomatous Disease, Job's Syndrome, Mycobacterium Infection, Wegener's Granulomatosis
Interventions
virtual bronchoscopy
Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 25, 2026, 5:02 PM EDT
Active, not recruiting Phase 2 Interventional

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

NCT06449209
View directory record Official record
Conditions
Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
Interventions
BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide, Carboplatin, Paclitaxel, Topotecan
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Anchorage, Alaska • Los Angeles, California • Clermont, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jun 25, 2026, 5:02 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension

NCT00350844
View directory record Official record
Conditions
Sickle Cell Disease, Pulmonary Hypertension
Interventions
Hydroxyurea
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
10 Years to 25 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Jun 25, 2026, 5:02 PM EDT
Completed Phase 3 Interventional

Ventilatory Muscle Training in Stroke

NCT02828943
View directory record Official record
Conditions
Stroke, Pulmonary Ventilation, Exercise Therapy
Interventions
IMT with High Resistance EMT, IMT with Low Resistance EMT
Behavioral
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Jun 25, 2026, 5:02 PM EDT
Terminated Early Phase 1 Interventional Results available

Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)

NCT00763035
View directory record Official record
Conditions
Coronary Artery Disease, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Angina
Interventions
Regadenoson, Dobutamine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Jun 25, 2026, 5:02 PM EDT
Completed Phase 1Phase 2 Interventional

Real-time MRI Right Heart Catheterization Using Passive Catheters

NCT01287026
View directory record Official record
Conditions
Caridovascular Disease, Congenital Heart Disease, Pulmonary Hypertension
Interventions
Cardiac Real-time MRI RHC (Right Heart Catheterization)
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 99 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Jun 25, 2026, 5:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy

NCT04063215
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Jun 25, 2026, 5:02 PM EDT
Recruiting No phase listed Observational

One-Time DNA Study for Vasculitis

NCT01241305
View directory record Official record
Conditions
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Giant Cell Arteritis, Granulomatosis With Polyangiitis (Wegener's), Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu's Arteritis
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
7 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2028
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jun 25, 2026, 5:02 PM EDT